spacer
home > pmps > spring 2019 > the importance of product master data
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Importance of Product Master Data

By November 2019, wholesale distributors will be required to verify the serialised product identifiers for any saleable products that have been returned to them before they can be restocked and resold. With this new saleable returns verification requirement, the challenges of master data exchange for manufacturers will come to the fore.

To manage the scope, scale, and challenges of the saleable returns requirement, wholesalers and manufacturers must re-evaluate their current methods of exchanging product master data information.

The Scale of the Challenge

The national organisation representing primary wholesale distributors in the US, the Healthcare Distribution Alliance (HDA), executed analysis of saleable returns. This showed that approximately 60 million units of drug product are returned annually, with the majority of saleable returns caused by overstocking (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dan Walles is the General Manager of Track & Trace and Compliance at TraceLink, where he brings more than 20 years of experience in product management, solution consulting, and service delivery to his role. He has focused exclusively on the needs of the life sciences industry for the past 15 years. Since joining TraceLink in 2010, Dan has been instrumental in educating customers on TraceLink’s Life Sciences Cloud and partner ecosystem to enable compliance and added business value through supply chain visibility and improved patient outcomes.
spacer
Dan Walles
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement